Source: Australian Financial Review

EnGeneIC: Cancer biotech raising $20m after delaying Nasdaq float

EnGeneIC has clinical trials under way using its nanocell technology in cancer and COVID-19, and now plans to list in the US next year.

Read full article »
EnGeneIC's Competitors | EnGeneIC's News | EnGeneIC's Financials
Stay up-to-date with the latest news on EnGeneIC
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Himanshu Brahmbhatt's photo - Co-CEO of EnGeneIC

Co-CEO

Himanshu Brahmbhatt

CEO Approval Rating

68/100

Read more
Stay up-to-date with the latest news on EnGeneIC